<?xml-model href='http://www.tei-c.org/release/xml/tei/custom/schema/relaxng/tei_all.rng' schematypens='http://relaxng.org/ns/structure/1.0'?><TEI xmlns="http://www.tei-c.org/ns/1.0">
	<teiHeader>
		<fileDesc>
			<titleStmt><title level='a'>A nanobody-based strategy for rapid and scalable purification of human protein complexes</title></titleStmt>
			<publicationStmt>
				<publisher>Nature protocols</publisher>
				<date>01/01/2024</date>
			</publicationStmt>
			<sourceDesc>
				<bibl> 
					<idno type="par_id">10553283</idno>
					<idno type="doi">10.1038/s41596-023-00904-w</idno>
					<title level='j'>Nature Protocols</title>
<idno>1754-2189</idno>
<biblScope unit="volume">19</biblScope>
<biblScope unit="issue">1</biblScope>					

					<author>Taylor Anthony Stevens</author><author>Giovani Pinton Tomaleri</author><author>Masami Hazu</author><author>Sophia Wei</author><author>Vy N Nguyen</author><author>Charlene DeKalb</author><author>Rebecca M Voorhees</author><author>Tino Pleiner</author>
				</bibl>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<abstract><ab><![CDATA[The isolation of proteins in high yield and purity is a major bottleneck for the analysis of their three-dimensional structure, function and interactome. Here, we present a streamlined workflow for the rapid production of proteins or protein complexes using lentiviral transduction of human suspension cells, combined with highly specific nanobody-mediated purification and proteolytic elution. Application of the method requires prior generation of a plasmid coding for a protein of interest (POI) fused to an N-or C-terminal GFP or ALFA peptide tag using a lentiviral plasmid toolkit we have designed. The plasmid is then used to generate human suspension cell lines stably expressing the tagged fusion protein by lentiviral transduction. By leveraging the picomolar affinity of the GFP and ALFA nanobodies for their respective tags, the POI can be specifically captured from the resulting cell lysate even when expressed at low levels and under a variety of conditions, including detergents and mild denaturants. Finally, rapid and specific elution of the POI (in its tagged or untagged form) under native conditions is achieved within minutes at 4 °C, using the engineered SUMO protease SENP EuB . We demonstrate the wide applicability of the method by purifying multiple challenging soluble and membrane protein complexes to high purity from human cells. Our strategy is also directly compatible with many widely used GFP-expression plasmids, cell lines and transgenic model organisms. Finally, our method is faster than alternative approaches, requiring only 8 d from plasmid to purified protein, and results in substantially improved yields and purity.
Key points• The protocol describes the lentivirus-based expression of high amounts of soluble and membrane-bound tagged proteins of interest (POI) in human suspension cells. This is combined with rapid nanobody-based purification of the POI and its complexes for downstream structural analysis and functional assays.• The protocol provides guidelines for the isolation of a POI in its tagged (TagON) and scarless untagged (TagOFF) forms using an engineered SUMO protease (SENP EuB ).]]></ab></abstract>
		</profileDesc>
	</teiHeader>
	<text><body xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>A key prerequisite for many basic and pharmacological applications is the preparation of highly pure protein samples. Sample quality underlies the success of diverse experimental techniques including structural approaches (e.g., cryo-electron microscopy (cryo-EM) and X-ray crystallography), proteomics (e.g., interactome studies) and high-throughput studies of protein function (e.g., biophysical assays or in vitro drug screens).</p><p>Human proteins can be notoriously difficult to express and purify at the scale and purity needed for their structural and functional characterization. Their heterologous expression (e.g., in bacteria) frequently results in extensive degradation, formation of insoluble aggregates or lack of essential posttranslational modifications. These problems are exacerbated for multisubunit protein complexes and membrane proteins, which may rely on mammalian-specific factors for their biogenesis. Mammalian expression systems are thus, in many cases, the only alternative. However, culturing mammalian cells can be costly, making it essential to streamline both expression and protein purification workflows, to maximize yield and purity while saving valuable time and resources.</p><p>Here, we present a rapid and easily scalable workflow to purify soluble and membranespanning human proteins and protein complexes from human suspension cells for their structural and functional analysis. Our workflow combines advances in both expression cell line generation <ref type="bibr">1</ref> and purification strategy <ref type="bibr">2</ref> , and employs two highly versatile and complementary affinity tags, GFP and the small ALFA peptide tag <ref type="bibr">3</ref> .</p><p>First, we describe how to rapidly generate stable polyclonal human suspension cell lines expressing a GFP-or ALFA-tagged protein of interest (POI) using lentiviral transduction. The use of lentivirus combines multiple advantages of both transient transfection and monoclonal cell line generation <ref type="bibr">1</ref> . In fact, lentivirus allows users to quickly generate stable cell lines within only a few days, using lentivirus produced from a single well of a six-well plate. Also, it enables highly tunable expression: transduction efficiencies can be titrated to either &gt;80-90% to maximize yield, or to &lt;30% to ensure a single copy of cDNA per cell. When coupled with fluorescence-activated cell sorting (FACS), polyclonal cell lines can be generated that contain uniform expression across all cells. Finally, lentivirus ensures reproducible and scalable expression, because once generated, cell lines can be stored or expanded indefinitely. To streamline the cloning of suitable expression plasmids, we provide an extensive plasmid toolbox (Table <ref type="table">1</ref>), an accompanying cloning guide (Supplementary Data 1) and general recommendations for GFP/ALFA tag placement.</p><p>Second, we present a nanobody (Nb)-based strategy for the isolation of the tagged POI under native conditions, which ensures higher yield and purity than canonical epitope tag-based approaches. This is achieved through the combination of high-affinity binding to anti-GFP or ALFA nanobodies with selective elution by an engineered SUMO protease (SENP EuB ) <ref type="bibr">4</ref> . SENP EuB allows nearly 1,000-fold faster release of resin-bound proteins than tobacco etch virus (TEV) or 3C proteases, and elution can therefore be performed quickly under gentle conditions on ice. Rapid and selective elution of Nb-captured proteins ensures high sample purity and preserves delicate protein complexes. We provide details on bacterial expression plasmids and protocols to inexpensively produce both nanobodies and protease in amounts sufficient for hundreds of purifications.</p><p>Through the combination of lentivirus-based cell line generation and Nb-mediated affinity purification, our protocol reduces the time and costs required to prepare high-quality protein samples. Together, these strategies can therefore substantially accelerate the structural and functional analysis of otherwise difficult-to-express human protein complexes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Applications</head><p>One advantage of this protocol is that the Nb-based purification strategy is highly flexible and modular. It can be used for purification of proteins or protein complexes under a variety of conditions, and from lysates prepared from various eukaryotic or prokaryotic sources. In particular, utilizing the anti-GFP Nb for protein capture, our method can leverage the vast Protocol number of existing sources for GFP-tagged proteins (e.g., yeast, flies, worms and mice) <ref type="bibr">[5]</ref><ref type="bibr">[6]</ref><ref type="bibr">[7]</ref><ref type="bibr">[8]</ref><ref type="bibr">[9]</ref><ref type="bibr">[10]</ref> . Publicly available and commercial sources are enumerated in Supplementary Table <ref type="table">1</ref>. Further, the Nb-affinity tag pair can easily be exchanged to other natural, laboratory-evolved or computationally designed binding proteins, as well as protein-specific binders <ref type="bibr">11,</ref><ref type="bibr">12</ref> , making the system highly adaptable. A selection of potential options are listed in Supplementary Table 2 (refs. 13-21). We therefore envision that this strategy will be suitable for any structural or functional application requiring protein purification from cells, extract or tissue.</p><p>One particularly powerful application of this protocol is generating samples for structural analysis, which requires large-scale production of highly pure samples <ref type="bibr">2,</ref><ref type="bibr">22</ref> . For example, we have used this strategy to purify the nine-subunit human endoplasmic reticulum (ER) membrane protein complex (EMC), for structure determination using single-particle cryo-EM <ref type="bibr">2</ref> . For the EMC, and many other protein complexes, we have found that expression of a single tagged subunit results in its incorporation into the intact complex in place of the endogenous subunit. Any excess unassembled subunits are typically degraded by the ubiquitin-proteasome pTP396 His 14 -Avi-27xGS-SUMO Eu -19xGS-anti GFP Nb 149336 pTS117 His 14 -Avi-45xGS-anti GFP Nb 199370 pTP298 His 14 -Avi-27xGS-SUMO Eu -2xGS-anti ALFA tag Nb 199390 pTS118 His 14 -Avi-28xGS-anti ALFA tag Nb 199371 pAV0286 His 14 -TEV-SENP EuB protease 149333 pTP264 His 14 -bdNEDD8-BirA 149334</p><p>All plasmids are available from Addgene for use in academic research. 3C, human rhinovirus 3C protease recognition site; GS, glycine/serine-rich spacer of indicated length in aa; MCS, multiple cloning site; TEV, tobacco etch virus protease recognition site.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p>pathway, as has been previously described <ref type="bibr">23,</ref><ref type="bibr">24</ref> . Therefore, by exploiting endogenous protein quality control machinery in human cells, it is often possible to introduce a tag into a protein complex without expressing multiple subunits or first generating knockout cell lines. Similarly, our protocol can be used to generate highly pure samples for functional assays (e.g., to characterize a protein's enzymatic activity, stability or DNA-/RNA-/lipid-binding properties). We recently used it to isolate the 33 kDa mitochondrial outer membrane insertase MTCH2 to reconstitute its protein-insertion activity in vitro <ref type="bibr">25</ref> .</p><p>Further, because of the high specificity, efficient capture and rapid elution, this protocol is also well suited for analysis of physical interaction partners by mass spectrometry (K. Page, V.N.N. and T.P., unpublished observation).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overview of the procedure</head><p>After cloning of the POI into a lentiviral transfer plasmid as a GFP-or ALFA-tag fusion (Supplementary Data 1), our protocol comprises three main stages (Fig. <ref type="figure">1</ref>) that can be carried out in parallel and can be summarized as follows:</p><p>&#8226; In its fastest format, our procedure can be completed in only 8 d; however, the daily workload can be reduced by using the multiple pause points highlighted in the 'Procedure' section. In addition, some steps are marked as 'optional' and performing them will require additional time. However, researchers should consider implementing them as quality control procedure for critical reagents or to obtain higher final sample yield (sorting) and homogeneity (size-exclusion chromatography (SEC)). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generation of stable</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Two purification strategies: TagON and TagOFF</head><p>We present two different strategies to purify a GFP-or ALFA-tagged protein in either a tagged (TagON) or scarless untagged form (TagOFF) (Fig. <ref type="figure">2</ref>). Both strategies employ biotinylated anti-GFP or ALFA nanobodies that are immobilized onto streptavidin beads to capture GFPor ALFA-tagged proteins from cell lysate. In the TagON strategy (Fig. <ref type="figure">2a</ref>), a SUMO Eu module is inserted between the biotin acceptor peptide (Avi) tag and Nb, so that SENP EuB cleavage releases the Nb along with its bound protein. The eluted protein therefore retains the desired tag, which may be useful for detection during downstream applications, such as fluorescence detection SEC <ref type="bibr">26</ref> . In the TagOFF strategy (Fig. <ref type="figure">2b</ref>), a SUMO Eu module is placed in between GFP/ALFA tag and the protein so that cleavage by SENP EuB only releases the protein while both Nb and tag are retained on the resin. This strategy is useful if the presence of the tag interferes with downstream applications.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparison with other methods</head><p>The advantages of this purification protocol over existing methods stem primarily from combining two innovations. First, we achieve higher sample purity by using highly specific nanobodies and affinity beads. Our approach exploits the picomolar affinity between the nanobodies and their epitope tags to selectively capture tagged proteins from cell lysate. Additionally, both the Nb fusion proteins and affinity resin are fully orthogonal to eukaryotic and prokaryotic host proteins. For example, the Nb-decorated streptavidin beads are passivated by blocking any excess binding sites with free biotin or charged PEGylated biotin derivatives. Therefore, in contrast to the TwinStrep:Streptactin system <ref type="bibr">27</ref> , our strategy does not capture endogenous biotinylated proteins.</p><p>Second, rapid and selective protease elution of Nb-captured proteins additionally ensures high sample purity and quality. In contrast, commonly used epitope tag-binding monoclonal antibodies (e.g., FLAG, HA, Myc or V5), rely on native elution using excess epitope peptide. This is often highly inefficient and requires prolonged incubation at room temperature (RT; 23-25 &#176;C), which releases background binders, causes aggregation of fragile proteins </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p>or dissociation of weaker binding partners. A side-by-side comparison shows that EMC isolated from an EMC5-GFP cell line using SENP EuB cleavage is substantially purer than EMC isolated from an EMC5-3&#215;FLAG cell line using traditional anti-FLAG purification (Fig. <ref type="figure">3a</ref>). The combination of specific nanobodies, passivated affinity resin and protease elution therefore yields high final sample purity.</p><p>Protease cleavage is thus a powerful alternative over inefficient competitive peptide elution. However, common proteases, such as human rhinovirus 3C protease or TEV protease, inefficiently cleave resin-bound proteins, especially on ice. Often, large amounts of contaminating protease and lengthy overnight incubations (&gt;13 h) are needed to circumvent these issues. In contrast, low nanomolar concentrations of SENP EuB are sufficient to gently release resin-bound proteins on ice within a few minutes (Fig. <ref type="figure">3b</ref>).</p><p>Through both innovations, our protocol thus improves the signal-to-noise ratio of affinity purifications and better preserves sensitive protein complexes and their transient interaction partners. This yields fewer false interactors for affinity purification mass spectrometry experiments and should also reduce contaminants that may interfere with functional experiments.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations</head><p>One limitation of this approach is that the ectopic expression of a protein complex subunit can, in some cases, result in its purification in excess over other endogenous complex members. This especially affects subunits that are stable in the unassembled state. Frequently, these excess subunits can be separated by an additional SEC purification step. However, multiple preventative measures can improve protein complex yield and stoichiometry. One strategy could involve the use of Freestyle 293-F suspension cells instead of Expi293F cells. Indeed, we observed that overexpression of unassembled subunits is more limited in these cells, probably  Elutions from either EMC5-FLAG (using M2 FLAG affinity resin (Millipore-Sigma)) or EMC5-GFP (using TagON) purifications performed at equivalent scale were analyzed by SDS-PAGE and Sypro Ruby staining. The results from this experiment demonstrate a strong reduction of the presence of contaminating proteins when using the TagON strategy compared with a traditional FLAG peptide elution. b, Comparison of 3C and SENP EuB protease on-column cleavage efficiency. Purification of EMC from a EMC5-3C-SUMO-GFP expressing cell line (using the TagOFF strategy). The cell lysate was incubated with magnetic streptavidin beads, containing immobilized noncleavable biotinylated anti-GFP Nb (expressed from pTS117). After washing, beads were split in half and incubated either with 2 &#181;M 3C or 250 nM SENP EuB protease at 4 &#176;C for the indicated time frames. Under these conditions, SENP EuB cleaves nearly 1,000-fold faster, allowing for rapid elution in just 1 min as opposed to lengthy overnight incubations typically required for elution with 3C or TEV protease. The products of 3C and SENP EuB cleavage are marked with red and blue arrows, respectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p>due to tighter regulation by the ubiquitin-proteasome system (unpublished observation, T.A.S. and T.P.). However, Freestyle 293-F cells cannot be grown to as high density as Expi293F cells, decreasing yield per liter of expression. As our lentiviral vectors are regulated by doxycycline-inducible promoters, the expression level of the POI can also be fine tuned by varying induction time in Expi293F TetR+ cells. Alternatively, the expression level can be reduced by exchanging the strong cytomegalovirus (CMV) promoter for a weaker one <ref type="bibr">28</ref> and/or by removing the expression-enhancing woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) element <ref type="bibr">29</ref> . If the POI is membrane bound, it can be beneficial to first enrich a membrane fraction to remove excess nonincorporated and aggregated subunits in the cytosol. Purification from the solubilized membrane fraction can therefore yield higher sample quality and better complex stoichiometry.</p><p>If these approaches do not yield the expected outcome, it is possible to overexpress multiple subunits in parallel. This can be achieved via cotransduction with multiple distinct lentiviral particles, via fusion of multiple subunits into a single expression plasmid using P2A sites <ref type="bibr">30</ref> or via a combination of the first two options. The efficiency of dual or triple transduction is typically lower than transduction with a single lentivirus. Multicolor sorting via FACS is therefore required to obtain a fully transduced cell line. Our lentiviral transfer plasmid toolbox already allows compatible GFP and blue fluorescent protein (BFP) expression plasmids to be generated. A third compatible plasmid can easily be generated by introducing mCherry.</p><p>Another limitation to consider is that the constitutive ectopic expression of a protein can be toxic or reduce cellular fitness. In a heterogeneous cell population containing untransduced cells, this can lead to a gradual loss of more slowly growing transduced cells. In such cases, the use of the inducible expression system is likely to alleviate the negative selection pressure resulting from the constitutive expression of a toxic protein. Alternatively, successfully transduced cells can be sorted via FACS to remove faster-growing untransduced cells.</p><p>The yield of lentiviral particles decreases sharply with increasing transfer plasmid size, resulting in strongly reduced titers for transfer plasmids encoding large proteins (e.g., inserts between 5&#8242; and 3&#8242; long-terminal repeats (LTRs) above 8 Kbp). After subtraction of essential elements, this leaves ~5 Kbp for the GFP-or ALFA-tagged POI (~180 kDa). If necessary, removal of the WPRE element can yield an extra ~600 bp.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expertise needed to implement the protocol</head><p>Our purification protocol requires only basic skills in recombinant protein production in E. coli and cell culture handling, and can even be carried out by undergraduate students with prior training. The generation of stable human suspension cell lines using lentiviral transduction, however, requires special biosafety training and conditions in compliance with the relevant institutional and governmental biosafety regulations. Elegheert and colleagues expertly summarized common safety practices associated with lentiviral work <ref type="bibr">1</ref> . However, if use of lentivirus is not feasible, multiple other strategies for plasmid delivery can be used instead (see below).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experimental design</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Preparation of Nb fusion proteins and SENP EuB protease</head><p>All recombinant proteins required for this protocol can easily be purified in very high yield and purity from single 1 L E. coli cultures (Steps 1-34). Such preparations generate sufficient reagents for hundreds of purifications from eukaryotic cells. We provide expression plasmids and protocols for the generation of SENP EuB protease, as well as biotinylated anti-GFP and anti-ALFA nanobodies with or without the SUMO Eu module in between the Avi-tag and Nb (for Addgene IDs, see Table <ref type="table">1</ref>).</p><p>The anti-GFP Nb can easily be biotinylated during expression in the E. coli strain AVB101, which allows IPTG-inducible co-expression of the biotin ligase BirA. The anti-ALFA Nb, however, expresses better in the E. coli Rosetta-gami2 strain, which does not express BirA. Purified ALFA Nb therefore needs to be biotinylated with purified BirA in solution (Box 1). For this, we provide a BirA expression plasmid (pTP264) and purification protocol. BirA can, however, also be obtained commercially.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p>Affinity resins containing immobilized (noncleavable) anti-GFP or ALFA nanobodies are commercially available and are directly compatible with the TagOFF strategy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Optimal introduction of a tag on a protein subunit or complex</head><p>The first critical consideration for the purification of a multisubunit protein complex is to choose a subunit to tag. We frequently found that ectopic expression of a single tagged subunit of a protein complex in human cells can result in the replacement of its endogenous counterpart <ref type="bibr">24</ref> . This strategy yields stoichiometric complexes in human cells when efficient cellular quality control mechanisms exist that degrade excess tagged and endogenous subunits of the chosen complex. Existing functional and structural data can often be used to inform subunit choice. For example, scaffold subunits of protein complexes typically contain multiple hydrophobic interfaces and are especially short lived in the unassembled state, ensuring rapid elimination of excess subunits. Such subunits might thus represent prime candidates for first tagging trials <ref type="bibr">24</ref> and can be identified from mass spectrometry studies that analyzed proteome-wide degradation kinetics <ref type="bibr">31</ref> . More stable subunits can accumulate after overexpression and may need to be removed by additional purification steps.</p><p>The next important consideration is to identify the optimal location of the affinity tag to minimize its interference with protein function and stability. For protein complexes, the tag must be compatible with complex assembly. Compatibility can often be inferred from prior published studies or large-scale GFP-tagging efforts (Supplementary Table <ref type="table">1</ref>), provided a careful analysis of localization and function was performed. Alternatively, existing structures or structural models of the protein can be analyzed. A flexible unstructured terminus that is not part of a folded domain can usually tolerate a protein tag. Conversely, regions with high</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Box 1</head><p>In vitro biotinylation of ALFA nanobodies with purified BirA</p><p>&#8226; TIMING 5 h &#9650; CRITICAl Ni 2+ -purified and buffer-exchanged ALFA nanobodies expressed from pTP298 and pTS118 are biotinylated with purified BirA in solution. Excess biotin then needs to be removed by an additional buffer exchange step. Procedure 1. Set up the biotinylation reaction mix as detailed in the table below: Component Amount ALFA Nb purified from pTP298 or pTS118 100 nmol BirA enzyme 1.5 nmol 5&#215; Biotinylation buffer 300 &#181;L ddH 2 O Up to 1.5 mL &#9650; CRITICAl STEP In vitro biotinylation is most efficient when the substrate is provided at a concentration of at least 40 &#181;M. Reaction volumes can be scaled up or down. 2. Incubate the reaction for 3 h at 25 &#176;C in a thermomixer without mixing. Mix by inverting the tube every 30 min.</p><p>&#9650; CRITICAl STEP BirA activity is highly temperature dependent.</p><p>If performed on ice the biotinylation reaction typically needs at least 24 h for completion.</p><p>3. Load the entire 1.5 mL biotinylation reaction on a PD-10 desalting column, pre-equilibrated in ALFA Nb storage buffer according to the manufacturer's instructions. 4. Wait for the entire volume of the reaction (1.5 mL) to completely sink into the column and discard the flow through. 5. Add 1 mL of ALFA Nb storage buffer and discard the flow through. 6. Elute stepwise by adding 0.5 mL of ALFA Nb storage buffer to the PD-10 desalting column and collect 6&#215; 0.5 mL fractions, each in a clean 1.5 mL Eppendorf tube. 7. Measure the absorbance of each individual fraction at 280 nm as in Step 28, as well as the 260/280 nm absorbance ratio. 8. In a fresh 2 mL tube, combine only fractions with a 260/280 ratio close to the ratio of the purified Nb before biotinylation (measured in Step 28).</p><p>&#9650; CRITICAl STEP The expected ratio should be between 0.5 and 0.7. Including later fractions with increased 260/280 ratios (&gt;0.7) risks contaminating the final biotinylated ALFA Nb preparations with excess free biotin that will compete with Nb binding to streptavidin beads. 9. Measure the final concentration as in Step 28 of the procedure, prepare aliquots as advised in Step 32 and flash-freeze them in liquid nitrogen.</p><p>&#9632; PAuSE POINT Frozen protein aliquots are stable at -80 &#176;C for years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p>sequence conservation might indicate a functional requirement or binding site. In general, smaller peptide tags (such as the ALFA tag) tend to be less disruptive than larger globular tags.</p><p>The ALFA tag can also be placed internally into exposed loops and thus provides an alternative for proteins that cannot be tagged at either terminus.</p><p>If the presence of a tag will interfere with downstream applications, the TagOFF strategy should be used to completely remove the tag during purification. For this, the appropriate noncleavable Nb fusion protein needs to be generated and combined with a protein expression vector that contains a protease cleavage site. As described below, N-terminal tags can be removed completely (scarless), yet C-terminal tag removal will always generate a cleavage scar.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cloning of a lentiviral transfer plasmid encoding the tagged POI</head><p>Once a tagging and purification strategy is identified, the coding sequence of the POI needs to be cloned into a lentiviral transfer plasmid. We provide an extensive toolbox of second generation lentiviral transfer plasmids to facilitate fusion of a POI to a GFP or ALFA tag. All plasmids are available via Addgene (for IDs, see Table <ref type="table">1</ref>). Each tag is either N-terminal (pTS93-pTS102) or C-terminal (pTS103-pTS116) and either noncleavable for TagON or cleavable for TagOFF purification (Supplementary Fig. <ref type="figure">1</ref>). A detailed cloning guide is provided in Supplementary Data 1.</p><p>All constructs contain a CMV promoter fused to two Tet operator sequences (CMV-TetO2), which are Tet repressor (TetR) binding sites. The CMV-TetO2 promoter is thus doxycycline inducible only in a TetR+ cell line but will otherwise express constitutively.</p><p>We strongly recommend homemade SENP EuB protease for tag removal, but we also provide plasmids encoding the cleavage sites of the commercially available 3C, TEV and SUMOstar proteases. As these proteases all cleave at the C-terminus of their recognition site, N-terminal tags can thus be nearly completely removed. For C-terminal tags, however, this results in a cleavage scar. The scars of 3C and TEV protease (both of six amino acids (aa) in length) are smaller than those of the SENP EuB (96 aa) and SUMOstar proteases (99 aa). If desired, these larger C-terminal scars can be removed after elution by an additional 3C or TEV protease cleavage step in solution. Our SUMO protease-cleavable C-terminal GFP-or ALFA-tag encoding plasmids thus contain additional 3C or TEV cleavage sites between multiple cloning site and SUMO module.</p><p>A final consideration when selecting the right construct is that protein yield can be maximized by isolating successfully transduced cells via FACS to obtain a homogeneous population. While cells expressing GFP-tagged proteins can easily be sorted using GFP fluorescence, we additionally equipped expression vectors encoding ALFA-tagged proteins with a TagBFP expression cassette. TagBFP is separated from the ALFA-tagged protein using a porcine teschovirus P2A sequence, which mediates peptide bond skipping by the ribosome <ref type="bibr">30</ref> and thus results in the efficient synthesis of two separate proteins from a single mRNA (i.e., TagBFP and the ALFA-tagged protein).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generation of stable human suspension cell lines using lentiviral transduction</head><p>Lentiviral particles can be generated by cotransfecting adherent Lenti-X 293T cells with a second generation lentiviral transfer plasmid encoding a GFP-or ALFA-tagged POI and second generation packaging (e.g., psPAX2) and envelope plasmids (e.g., pMD2.G) (Steps 35-49). Transfected cells secrete lentiviral particles into the culture medium that are pseudotyped with the VSV-G envelope protein, which binds the widely expressed low-density lipoprotein receptor on the target cell surface and thus confers broad host cell tropism <ref type="bibr">32</ref> . Lentiviral particles can then be used to transduce multiple human suspension and adherent cell lines that are compatible with our purification protocol.</p><p>We favor a very rapid, easy-to-use, lentiviral transduction approach 1 to generate stable cell lines expressing a GFP-or ALFA-tagged POI (Steps 50-61). Generally, we prefer Expi293F (TetR-) and Expi293F inducible cell lines (TetR+), because they maintain high viability even at very high cell density, and thus maximize the yield of cells per liter of culture medium. To express secreted or membrane proteins without complex N-glycans, the N-acetylglucosaminyltransferase I knockout (GnTI-) derivatives of these cell lines should be used.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p>During infection, lentiviral particle-containing culture medium is simply mixed with human Expi293F suspension cells. This leads to the stable integration of the open reading frame encoded on the transfer plasmid into a random genomic location. For first small-scale purification trials, we recommend expanding transduced cells to medium density in ~50 mL. This allows testing different tags, tag positions or expression conditions. For monomeric or homo-oligomeric proteins, a reduction of expression temperature from 37 &#176;C to 30 &#176;C or the inclusion of histone deacetylase inhibitors such as sodium butyrate or valproic acid were previously shown to lead to large increases of final protein yield <ref type="bibr">31</ref> . For individually expressed subunits of protein complexes, strong overexpression might reduce final complex yield and expression conditions instead need to be optimized to maximize subunit incorporation. Once optimal conditions are found, purifications from 1 to 2 L high-density cultures often provide enough material for structural and functional assays.</p><p>If lentiviral work is not feasible, multiple alternative approaches can be used instead to generate human suspension cell lines expressing a GFP-or ALFA-tagged POI. These include, for example, transient transfection using polyethylenimine or Expifectamine, baculovirus transduction <ref type="bibr">33</ref> and adaptation of stable adherent cell lines to suspension growth <ref type="bibr">34</ref> . Such stable adherent cell lines can be generated by Flp-In recombination <ref type="bibr">35</ref> , antibiotic selection <ref type="bibr">34</ref> or clustered regularly interspaced short palindromic repeats (CRISPR) knock-in <ref type="bibr">[36]</ref><ref type="bibr">[37]</ref><ref type="bibr">[38]</ref> .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell lysis method and purification conditions</head><p>The subcellular localization and stability of the POI dictates the appropriate lysis method to prepare cell extracts for affinity purification (Step 66). Mechanical lysis is appropriate to purify soluble cytosolic or nuclear proteins. Nuclear DNA-bound proteins additionally need to be dissociated from DNA using a high-salt lysis buffer <ref type="bibr">39</ref> . Membrane proteins must be solubilized from whole cells or enriched membrane fractions using detergents or other membrane mimetics <ref type="bibr">40,</ref><ref type="bibr">41</ref> . The choice of detergent for solubilization can affect membrane protein extraction efficiency and stability.</p><p>Another critical factor to consider is the protein's intrinsic stability. In general, lysis buffers with slightly elevated salt concentration (&gt;150 mM) and detergent can strongly reduce nonspecific binding of lysate proteins to affinity resins. For example, the widely used RIPA lysis buffer contains high concentrations of ionic (deoxycholate and sodium dodecyl sulfate (SDS)) and nonionic detergents (Triton-X-100 or NP-40) and is used for both soluble and membrane protein purification. Generally, these harsher detergents, if tolerated, enable purifications with higher purity; however, some proteins and protein complexes can be very sensitive to high ionic strength or detergents, and in this case, gentle detergents such as glyco-diosgenin (GDN) are strongly preferred to maintain protein stability as well as transient protein-protein interactions. To determine the optimal conditions for a protein or complex of interest, we recommend optimizing lysis buffer composition alongside expression conditions in pilot small-scale purification trials. For GFP-tagged proteins, this can be done using fluorescence detection SEC, as described before <ref type="bibr">26,</ref><ref type="bibr">33</ref> .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protein purification by Nb capture and protease release</head><p>The major components of our purification strategy are highly stable proteins that are compatible with the most commonly used lysis buffer compositions.</p><p>For example, we use the anti-GFP Nb Enhancer (12.8 kDa), which binds GFP with high affinity (K D ~ 590 pM) and specificity in many different systems <ref type="bibr">42,</ref><ref type="bibr">43</ref> . Various widespread GFP variants (including wildtype (WT) GFP, EGFP and superfolder GFP <ref type="bibr">44</ref> ), as well as closely related fluorescent proteins, are compatible (Extended Data Fig. <ref type="figure">1</ref>). The ALFA Nb (13.4 kDa) binds a rationally designed, 15 aa &#945;-helical peptide with very high affinity (K D ~ 26 pM) <ref type="bibr">3</ref> . Both nanobodies, as well as GFP and ALFA tags are stable and bind efficiently even under harsh conditions, including high concentrations of most detergents, salt and even urea (Supplementary Table <ref type="table">3</ref>).</p><p>For our purification strategies (Steps 67-89), both nanobodies are immobilized onto streptavidin beads using a fused biotin acceptor peptide (Avi tag), which is modified with a single biotin moiety by the biotin ligase BirA, either during expression in E. coli or Protocol after purification in vitro <ref type="bibr">[45]</ref><ref type="bibr">[46]</ref><ref type="bibr">[47]</ref> . As one of the strongest noncovalent interactions in nature, the biotin-streptavidin interaction withstands harsh purification conditions.</p><p>Finally, our protocol makes use of the SUMO Eu protein (10.5 kDa), which was engineered by the G&#246;rlich laboratory (Max Planck Institute for Multidisciplinary Sciences, Germany) to be resistant against cleavage by endogenous eukaryotic SUMO proteases <ref type="bibr">4</ref> . SUMO Eu -tagged nanobodies or proteins are thus stable in a variety of eukaryotic cells and cell extracts. The more commonly used yeast SUMO is useful for expression in prokaryotic systems, but is very rapidly cleaved in eukaryotic cells and cell lysate <ref type="bibr">4,</ref><ref type="bibr">48</ref> . The engineered SUMO Eu &#8226;SENP EuB pair therefore extends the use of the SUMO protease technology to eukaryotes. A similar but completely orthogonal SUMOstar system <ref type="bibr">49</ref> is commercially available (LifeSensors), but is slightly less resistant against host SUMO protease cleavage <ref type="bibr">4</ref> .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Controls</head><p>If our protocol is to be used for the identification of interaction partners via mass spectrometry, it is important to include controls to account for trace contaminants that nonspecifically bind to the affinity tag, Nb or affinity resin. A good control is a matched cell lysate expressing solely the affinity tag without a fused protein (e.g., only GFP, generated using plasmid pTP924). Less optimally, the cell lysate containing the POI can be split into two even fractions and additionally incubated with beads that either do not contain any immobilized Nb or that contain a nonspecific Nb (e.g., anti-ALFA Nb for a GFP-tagged protein).</p><p>Similarly, for functional assays, it is important to control that the observed activity of the purified protein is not caused by a contaminant. If possible, a catalytically dead mutant should be purified in parallel under identical conditions.</p><p>For cell sorting enrichment, nontransduced (negative) and single-color (positive) controls are typically required to determine efficient sort gate placement. Including these controls is even more important when sorting cell lines transduced with multiple different lentiviruses, encoding compatible fluorescent proteins, to allow multicolor compensation to correct for cross-channel fluorescence bleed through. Plasmids pTP341 and pTP924, which respectively express TagBFP and GFP both from a constitutive CMV promoter, can be used for this purpose (Table <ref type="table">1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biological materials</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell lines</head><p>&#8226; Lenti-X 293T cell line (Takara Bio, cat. no. 632180)</p><p>&#8226; Gibco Expi293F cells (TetR-; Thermo Fisher Scientific, cat. no. A14527; RRID: CVCL_D615) &#8226; Gibco Expi293F GnTI-cells (TetR-; Thermo Fisher Scientific, cat. no. A39240; RRID: CVCL_B0J7) &#8226; Gibco Expi293F inducible cells (TetR+; Thermo Fisher Scientific, cat. no. A39241; RRID: CVCL_B0J8) &#8226; Gibco Expi293F inducible GnTI-cells (TetR+; Thermo Fisher Scientific, cat. no. A39242; RRID: CVCL_B0J9) &#8226; Gibco Freestyle 293-F cell line (Thermo Fisher Scientific, cat. no. R79007; RRID: CVCL_D603) E. coli strains &#8226; NEBExpress I q chemically competent cells (New England Biolabs, cat. no. C3037I) &#8226; AVB101 chemically competent cells (Avidity, cat. no. CVB101) &#8226; Stellar competent cells (Takara Bio, cat. no. 636763) &#9650; CRITICAl Cloning DNA with repetitive elements, such as our lentiviral transfer plasmid toolbox, requires a recA-E. coli strain such as E. coli Stellar. &#8226; Rosetta-gami 2 competent cells (Novagen/Millipore-Sigma, cat. no. 71350-3) Protocol Reagents Common reagents &#8226; Gibco Expi293 expression (Expi) medium (Thermo Fisher Scientific, cat. no. A14351-01) &#8226; Gibco FreeStyle 293 expression medium (Thermo Fisher Scientific, cat. no. 12338018) &#8226; Gibco Dulbecco's modified Eagle medium (DMEM), high glucose, no glutamine (Thermo Fisher Scientific, cat. no. 11960051) &#8226; Gibco l-glutamine 200 mM (100&#215; Gln) (Thermo Fisher, cat. no. 25030081) &#8226; Gibco penicillin-streptomycin 5,000 U/mL (100&#215; pen-strep) (Thermo Fisher Scientific, cat. no. 15070063) &#8226; HyClone FBS (Cytiva, cat. no. SH30071.03) &#8226; Gibco Dulbecco's phosphate-buffered saline (DPBS), no calcium, no magnesium (Thermo Fisher Scientific, cat. no. 14190136) &#8226; Gibco Trypsin-ethylenediaminetetraacetic acid (EDTA) (0.25%), phenol red (Thermo Fisher Scientific, cat. no. 25200056) &#8226; Dimethyl sulfoxide (DMSO) (Thermo Fisher Scientific, cat. no. A13280.36) &#8226; Gibco Opti-MEM I (1&#215;) reduced serum medium (Thermo Fisher Scientific, cat. no. 31985-062) &#8226; TransIT-293 transfection reagent (Mirus Bio, cat. no. MIR 2704) &#8226; LB medium, Miller (Fisher Scientific, cat. no. BP1426-2) &#8226; LB agar, Miller (Powder) (Fisher Scientific, cat. no. BP1425-500) &#8226; Tryptone (Fisher Scientific, cat. no. BP9726-5) &#8226; Yeast extract granulated (Fisher Scientific, cat. no. BP9727-5) &#8226; Super Optimal broth with Catabolite repression (SOC) recovery medium (Thermo Fisher Scientific, cat. no. 15544034) &#8226; Carbenicillin (disodium salt) (Fisher Scientific, cat. no. BP26485) &#8226; Kanamycin (kan) sulfate (Fisher Scientific, cat. no. BP906-5) &#8226; Chloramphenicol (cam) (Fisher Scientific, cat. no. BP904-100) &#8226; IPTG (Millipore-Sigma, cat. no. I6758-5G) &#8226; Imidazole (Millipore-Sigma, cat. no. I2399-500G) &#8226; NaCl (Fisher Scientific, cat. no. S9888-5KG) &#8226; Tris base, Trizma (Millipore-Sigma, cat. no. T6066-5KG) &#8226; HEPES (Millipore-Sigma, cat. no. H3375-500G) &#8226; 1 M Magnesium acetate solution (Millipore-Sigma, cat. no. 63052-100ML) &#8226; Magnesium chloride (VWR, cat. no. MK5958-04) &#8226; Potassium acetate (Millipore-Sigma, cat. no. 60035-1KG) &#8226; Hydrochloric acid concentrated 37%/12 N (Millipore-Sigma, cat. no. HX0603-3) &#8226; Potassium hydroxide pellets (VWR, cat. no. 6984-06) &#8226; Glycerol (Fisher Scientific, cat. no. BP229-4) &#8226; Sucrose (Millipore-Sigma, cat. no. 50389-5KG) &#8226; DTT (Millipore-Sigma, cat. no. D9163-25G) &#8226; Ethanol 200 proof (VWR, cat. no. TX-89125172CAL) &#8226; Methanol (VWR, cat. no. BDH1135-4LG) &#8226; PMSF (Thermo Fisher Scientific, cat. no. 36978) &#8226; Ribonuclease A from bovine pancreas (Millipore-Sigma, cat. no. R6513-50MG) &#8226; Adenosine 5&#8242;-triphosphate dipotassium salt hydrate (Millipore-Sigma, cat. no. A8937-1G) &#8226; d-Biotin (Millipore-Sigma, cat. no. B4501-1G) &#8226; dPEG 24 -biotin acid (Quanta Biodesign, cat. no. 10773) &#8226; Triton-X-100 (Millipore-Sigma, cat. no. X100-500) &#8226; Tween-20 (Millipore-Sigma, cat. no. P1379-1L) &#8226; GDN (Anatrace, cat. no. GDN101 25 GM) &#8226; Doxycycline hyclate (Millipore-Sigma, cat. no. D9891-1G) &#8226; 20% (wt/vol) SDS (VWR, cat. no. 97062-442) &#8226; Bromophenol blue (Millipore-Sigma, cat. no. B0126-25G) &#8226; Urea (Millipore-Sigma, cat. no. U0631-500G) &#8226; Roche cOmplete EDTA-free protease inhibitor cocktail (Millipore-Sigma, cat. no. 11873580001) Protocol &#8226; Ni-NTA agarose resin 25 mL (Qiagen, cat. no. 30210) &#8226; Pierce streptavidin magnetic beads (Thermo Fisher Scientific, cat. no. 88816) Plasmids &#9650; CRITICAl All plasmids are available through the nonprofit Addgene plasmid repository and are subject to a Uniform Biological Material Transfer Agreement. Details of the plasmids supplied with this protocol are listed in Table 1. &#8226; E. coli expression plasmids: pTP264 (Addgene ID #149334)/pTP298 (Addgene ID #199390)/ pTP396 (Addgene ID #149336)/pTS117 (Addgene ID #199370)/pTS118 (Addgene ID #199371)/ pAV0286 (Addgene ID #149333) &#8226; Transfer plasmids: pTS093-pTS116 (Addgene ID #199346-199369)/pTP341 (Addgene ID #199391)/pTP924 (Addgene ID #199392) &#8226; pMD2.G lentivirus envelope plasmid (Addgene ID #12259) &#8226; psPAX2 lentivirus packaging plasmid (Addgene ID #12260)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sequencing primers</head><p>&#9650; CRITICAl These nonmodified DNA oligos are custom orders (Integrated DNA Technologies).</p><p>&#8226; CMV forward (5&#8242;-CGCAAATGGGCGGTAGGCGTG-3&#8242;)</p><p>Equipment &#8226; 125 mL Erlenmeyer flask, vent cap, plain bottom, polyethylene terephthalate glycol (PETG) (Celltreat, cat. no. 229801) &#8226; 490 cm 2 tissue culture treated roller bottle, vented cap (1 L roller bottle; Celltreat, cat. no. 229383) &#8226; 850 cm 2 tissue culture treated roller bottle, vented cap (2 L roller bottle; Celltreat, cat. no. 229385) &#8226; Tissue culture six-well plates (Genesee Scientific, cat. no. 25-105)</p><p>&#8226; Tissue culture 150 mm plates (Fisher Scientific, cat. no. FB012925) &#8226; 5 mL serological (Genesee Scientific, cat. no. 12-102) &#8226; 10 mL serological (Genesee Scientific, cat. no. 12-104) &#8226; 25 mL serological (Genesee Scientific, cat. no. 12-106) &#8226; 50 mL serological (Genesee Scientific, cat. no. 12-107)</p><p>&#8226; Steriflip sterile disposable vacuum filter units with pore size 0.22 &#181;m (Millipore-Sigma, cat. no. SCGP00525) &#8226; GenClone vacuum filter system with 0.22 &#181;m polyethersulfone (PES) membrane, 500 mL, sterile (Genesee Scientific, cat. no. 25-227) &#8226; Corning cryogenic vials, external thread (2.0 mL; Millipore-Sigma, cat. no. CLS430661) &#8226; 5 mL microcentrifuge tube, sterile (Eppendorf, cat. no. 0030119487) &#8226; 15 mL disposable centrifuge tube, sterile (Fisher Scientific, cat. no. 05-539-12) &#8226; 50 mL disposable centrifuge tube, sterile (Fisher Scientific, cat. no. 05-539-8) &#8226; 5 mL round-bottom flow cytometry tubes with strainer cap (VWR, cat. no. 76449-658) &#8226; Tissue culture CO 2 incubator (Thermo Fisher Scientific, model no. Heracell 240i) &#8226; Tissue culture S41i CO 2 incubator shaker (Eppendorf, cat. no. S41I120010) &#8226; Class II, type A2 biosafety cabinet (Baker, model: SterilGard III SG403) &#8226; Cell sorter (Sony Biotechnology, model no. SH800S) &#8226; Automated cell counter (Thermo Fisher Scientific, model no. Countess 3) &#8226; Cell counting slides (Bulldog-bio, cat. no. DHC-N01) &#8226; Tissue culture Floid cell imaging station (Thermo Fisher Scientific, cat. no. 4471136) &#8226; Benchtop centrifuge model no. 5810 with swing bucket rotor S-4-104 (Eppendorf, cat. no. 022627110) including 4&#215; 750 mL swing buckets + 15 mL conical tube Protocol adapters, as well as matching aerosol-tight caps (cat. no. 022638661) for lentiviral collection &#8226; Refrigerated floor centrifuge (Thermo Fisher Scientific, model no. Sorvall RC6+) with Fiberlite F9-4x1000y rotor &#8226; Corning CoolCell cell freezing vial container (Fisher Scientific, cat. no. 07-210-002) &#8226; Fast performance liquid chromatography system (Cytiva, model no. &#196;kta Pure 25 M) &#8226; SEC column (Cytiva, model no. Superose 6. Increase 3.2/300) &#8226; Hamilton gas-tight syringe 50 &#181;L (Millipore-Sigma, cat. no. 26280-U) &#8226; Amicon Ultra centrifugal filters for protein concentration (Millipore-Sigma, model no. Amicon Ultra 0.5 or 4 with protein-specific molecular weight cut-off (e.g., 3, 10, 30, 50 or 100 kDa)) &#8226; Disposable gravity-flow chromatography column, 20 mL (Bio-Rad, cat. no. 7321010) &#8226; PD-10 desalting columns (Cytiva, cat. no. 17085101) &#8226; Wheaton Dounce tissue grinder, 15 mL, tight pestle (DWK Life Sciences, cat. no. 357544) &#8226; Branson Ultrasonics sonifier SFX250 cell disruptor (Fisher Scientific, cat. no. 15-345-138) with disruptor horn (cat. no. 22-020860) &#8226; Invitrogen DynaMag-2 Magnet (Thermo Fisher Scientific, cat. no. 12321D) &#8226; Invitrogen DynaMag-15 Magnet (Thermo Fisher Scientific, cat. no. 12301D) (less expensive magnetic racks are available at <ref type="url">https://sergilabsupplies.com</ref>) Reagent setup lB medium To make 1 L of LB, dissolve 25 g of LB medium in 1 L of ddH 2 O. Sterilize by autoclaving for 45 min at 121 &#176;C using a liquid cycle. Store at RT for up to 1 year. Super broth (SB) To prepare 5 L of SB, weigh in 175 g tryptone, 100 g yeast extract, 25 g NaCl and dissolve in 4.5 L of ddH 2 O. Adjust the pH to 7-7.5 with 1 M NaOH and top up to 5 L. Aliquot 1 L into 2 L Erlenmeyer flasks and sterilize by autoclaving for 45 min at 121 &#176;C using a liquid cycle. Store at RT for up to 1 year. lB agar plates Dissolve 25 g LB agar in 1 L of ddH 2 O. Sterilize by autoclaving for 45 min at 121 &#176;C using a liquid cycle. When the solution has cooled to 45-50 &#176;C, add 1 mL of a 1,000&#215; stock of antibiotic, mix by swirling and pour into 100&#215; 15 mm Petri dishes. Allow to solidify and dry at RT. Store at 4 &#176;C for up to 6 months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="50">mg/ml Kanamycin (kan, 1,000&#215; stock)</head><p>To prepare 10 mL of a 50 mg/mL stock solution of kanamycin, dissolve 0.5 g of kanamycin sulfate in 9.5 mL of H 2 O. Top up the volume to 10 mL and filter-sterilize using a disposable Steriflip 0.22 &#181;m filter unit. Store in 1 mL aliquots at -20 &#176;C for up to 1 year.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="100">mg/ml Carbenicillin (1,000&#215; stock)</head><p>To prepare 10 mL of a 100 mg/mL stock solution of carbenicillin, dissolve 1 g of carbenicillin (disodium salt) in 9.5 mL of H 2 O. Top up the volume to 10 mL and filter-sterilize using a disposable Steriflip 0.22 &#181;m filter unit. Store in 1 mL aliquots at -20 &#176;C for up to 6 months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="50">mg/ml Chloramphenicol (cam, 1,000&#215; stock)</head><p>To prepare 10 mL of a 50 mg/mL stock solution of chloramphenicol, dissolve 0.5 g of chloramphenicol in 9.5 mL 100% ethanol. Top up the volume to 10 mL and filter-sterilize using a disposable Steriflip 0.22 &#181;m filter unit. Store in 1 mL aliquots at -20 &#176;C for up to 1 year.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">M IPTG</head><p>To make up</p><p>10 mL of 1 M IPTG, weigh in 2.38 g of IPTG and dissolve in 8 mL ddH 2 O. Top up the volume to 10 mL and filter-sterilize using a disposable Steriflip 0.22 &#181;m filter unit. Store in 1 mL aliquots at -20 &#176;C for up to 1 year. Protocol Wash buffer (-ATP) 50 mM HEPES/KOH pH 7.5, 200 mM NaCl, 2 mM MgAc, 0.01% (wt/vol) GDN, 1&#215; Roche cOmplete protease-inhibitor cocktail and 1 mM DTT. Prepare 1 mL by mixing 0.05 mL 1 M HEPES/KOH pH 7.5, 0.04 mL 5 M NaCl, 0.002 mL 1 M MgAc, 0.001 mL 10% (wt/vol) GDN, 0.04 mL 25&#215; Roche cOmplete protease-inhibitor cocktail, 0.001 mL 1 M DTT and 0.866 mL ddH 2 O. Prepare freshly before use. DMEM/10% FBS/1&#215; Gln medium (DMEM:FBS:Gln) Add 50 mL 100% FBS and 5.5 mL 100&#215; l-glutamine to 500 mL Gibco DMEM culture medium. (Optional) Add 5.5 mL 100&#215; pen-strep. Procedure Part 1: generation of biotinylated nanobodies, SENP EuB protease and biotin ligase BirA &#8226; TIMING 4-5 d &#9650; CRITICAl During the procedure, take samples for SDS-PAGE to help troubleshooting protein expression and purification as described in Supplementary Data 2. 1. Thaw one vial of the desired E. coli strain on ice for 10 min and add 1 &#181;L of the relevant plasmid at a concentration of 100 ng/&#181;L, following the guidelines provided in the table below: Protein Plasmid E. coli strain Antibiotic selection GFP Nb pTP396 and pTS117 AVB101 50 &#181;g/mL kan and 10 &#181;g/mL cam SENP EuB protease pAV0286 NEBExpress 50 &#181;g/mL kan BirA pTP264 NEBExpress 50 &#181;g/mL kan ALFA Nb pTP298 and pTS118 Rosetta-gami 2 50 &#181;g/mL kan and 34 &#181;g/mL cam &#9650; CRITICAl STEP The ALFA Nb does not express well in E. coli AVB101 and thus needs to be expressed in the alternative strain Rosetta-gami 2, which does not support biotinylation during expression. The resulting anti-ALFA tag nanobodies therefore need to be biotinylated in vitro after Ni 2+ -chelate affinity purification and buffer exchange, following the procedure described in Box 1. 2. Mix the sample by flicking the tube and incubate for 30 min on ice. 3. Heat shock the cells at 42 &#176;C for 30 s before quickly transferring the sample on ice and incubating for 1 min. 4. Resuspend heat-shocked cells in 300 &#181;L SOC recovery medium that was prewarmed to 37 &#176;C and incubate at 37 &#176;C for 1 h in a thermomixer, while shaking at 1,300 rpm. 5. Plate 50 &#181;L of transformed cells onto an LB agar plate containing the appropriate antibiotics (see table above) using the dilution streaking method to obtain single colonies. &#9650; CRITICAl STEP The cam addition to the LB agar plate and SB medium is required to maintain the BirA expression plasmid in the E. coli strain AVB101, as well as the pRARE plasmid in the E. coli Rosetta-gami 2 strain (see table above). 6. Incubate the plate at 37 &#176;C overnight. 7. The following morning, pick a single colony from the plate using a toothpick or pipette tip and transfer into a clean 1.5 mL Eppendorf tube containing 200 &#181;L SB medium, supplemented with the appropriate antibiotics (see table above). 8. Incubate shaking at 37 &#176;C for 4-5 h and then inoculate the cells into 100 mL of SB medium containing the appropriate antibiotics (see table above) in a 2-5 L baffled flask. 9. Incubate the preculture at 37 &#176;C overnight with shaking at 220 rpm. 10. The next morning, prepare a 1:10 dilution of the preculture in SB medium and measure the optical density of the diluted sample at 600 nm (OD 600 ) using a spectrophotometer. 11. Dilute the preculture with SB medium plus antibiotics to an OD 600 of ~1 to make up 1 L of main culture. Protocol 12. (Optional) For expression of the anti-GFP Nb in E. coli AVB101, weigh in 12.2 mg of biotin powder, resuspend in 1 mL of SB medium by vortexing briefly and add to the main culture. &#9650; CRITICAl STEP The suggested final concentration of biotin in the expression culture is 50 &#181;M. &#9650; CRITICAl STEP Biotin supplementation is crucial for efficient biotinylation of the expressed nanobodies. Biotin supplementation is unnecessary for SENP EuB protease, biotin ligase BirA and ALFA nanobodies. 13. Incubate the main culture at 18 &#176;C with shaking for at least 1 h to accommodate the expression culture to this temperature. 14. Add 0.2 mM IPTG to the main culture to induce protein expression. 15. Incubate the induced main culture overnight at 18 &#176;C if isolating anti-GFP nanobodies, or for 6 h at 18&#176;C if isolating SENP EuB protease, biotin ligase BirA and ALFA nanobodies. The culture needs to be maintained under constant agitation at ~220 rpm. 16. Collect cells by centrifugation at 9,220g for 10 min at 4 &#176;C. 17. Discard the supernatant and resuspend the cell pellet in 120 mL resuspension buffer. 18. Prepare 30 mL aliquots in 50 mL tubes and freeze in liquid nitrogen for a single freeze-thaw lysis cycle. &#9650; CAuTION Wear safety goggles when handling liquid nitrogen. &#9632; PAuSE POINT Frozen E. coli cells can be stored at -80 &#176;C for many months. 19. Rapidly thaw all frozen 50 mL tubes containing resuspended cells in lukewarm water and place on ice as soon as the last frozen clumps are thawed. 20. Combine thawed contents of all tubes and place the cell suspension into a 250 mL thin-walled metal beaker and transfer into an ice-water bath. 21. Lyse the cells by sonication using a Branson sonifier equipped with a flat tip. Perform four cycles of sonication, each 1 min long, at 100% amplitude. During each sonication cycle alternate 1 s pulse, with 2 s breaks. In between cycles, mix the cell lysate by swirling and allow to cool down for a minimum of 30 s, up to 1 min. &#9650; CRITICAl STEP Sonication creates heat that can activate E. coli proteases and denature proteins, causing degradation, aggregation or excessive chaperone binding. Always keep the cell suspension in an ice-water bath. Ideally perform sonication in a 4 &#176;C cold room. Keep the sonication probe properly submerged in the cell lysate to prevent foam formation and therefore protein aggregation. 22. Centrifuge the lysate for 30 min at 35,000g and 4 &#176;C. Take off and pool the supernatant. &#9632; PAuSE POINT Lysate can be supplemented with either 250 mM sucrose or 10% vol/vol glycerol, and frozen in liquid nitrogen for storage at -80 &#176;C for many months. 23. Equilibrate 2 mL settled Ni-NTA agarose resin with 20 mL resuspension buffer in a disposable 20 mL gravity flow column. Attach a long and wide, ideally blunt-ended, needle to the column to enhance the drip speed. &#9650; CRITICAl STEP For the purification of the anti-GFP Nb, use 2&#215; separate columns with 3 mL of settled Ni-NTA agarose resin in each column. 24. Transfer the equilibrated resin to a 250 mL glass bottle by resuspending it with 120 mL of cell lysate, and incubate for 1 h at 4 &#176;C, with constant mixing. &#9650; CRITICAl STEP Store the column and re-use in step 25 below. 25. Transfer the suspension back to the column (Step 23) and discard the flow through. 26. Wash the resin four times as detailed in the table below: Wash cycle Buffer Volume (ml) 1 Resuspension buffer 20 2 LSBAR buffer 20 3 High-salt buffer 20 4 Resuspension buffer 20 &#9650; CRITICAl STEP If purifying the SENP EuB protease and the biotin ligase BirA, replace the LSABR buffer with low-salt ATP buffer (without biotin and RNase A).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p>27. If using a needle to increase the flow, detach the needle, apply 1 mL imidazole elution buffer and discard the flow through. Elute stepwise by adding 0.5 mL imidazole elution buffer to the resin. Collect a total of 6&#215; 0.5 mL fractions in separate 1.5 mL tubes. &#9650; CRITICAl STEP If purifying the anti-GFP nanobody, apply 1.5 mL imidazole elution buffer to 3 mL resin and discard flow-through. Then collect 8&#215; 0.5 mL fractions in separate 1.5 mL tubes. 28. Measure the UV absorbance of each fraction at 280 nm using a nanodrop and pool together fractions with the highest protein content. Make sure to use imidazole elution buffer as a blank control. 29. Estimate the concentration of the pooled purified protein using its specific extinction coefficient at 280 nm (&#949; 280 ) (Table <ref type="table">2</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="30.">Analyze protein expression and purification samples, collected as outlined in</head><p>Supplementary Data 2, using SDS-PAGE and Coomassie staining. Compare the purified protein with Fig. <ref type="figure">4a</ref>. &#9670; TROuBlESHOOTING 31. (Optional) If purifying biotin ligase BirA or ALFA nanobodies, exchange the imidazole elution buffer to BirA storage buffer or ALFA Nb storage buffer, respectively, using a PD-10 desalting column. Purified ALFA nanobodies need to be further biotinylated in vitro with purified biotin ligase BirA, following the procedure outlined in Box 1. &#9650; CRITICAl STEP BirA activity is sensitive to ionic strength and glycerol concentration. 32. Aliquot the purified proteins into multiple 10 and 50 &#181;L aliquots in thin-walled 200 &#181;L PCR tubes and flash freeze in liquid nitrogen. Store aliquots in small boxes or 50 mL tubes at -80 &#176;C. &#9650; CRITICAl STEP Although aliquots typically tolerate multiple freeze-thaw cycles, repeated freeze-thawing or prolonged incubation at elevated temperatures will result in protein aggregation. Mark freeze-thaw cycles on the tubes and keep aliquots on ice immediately after thawing. &#9632; PAuSE POINT Frozen protein aliquots are stable at -80 &#176;C for years. 33. (Optional) Assess the biotinylation efficiency of purified nanobodies by following the procedure in Box 2 (Fig. <ref type="figure">4b</ref>). &#9650; CRITICAl STEP This is an optional quality control or troubleshooting step for the purified nanobodies. The percentage of nonbiotinylated nanobodies in the purified protein sample is ideally close to 100%. Lower biotinylation efficiencies can be accounted for in Part 3 by immobilizing more micrograms of of total Nb. 34. (Optional) Assess the activity of purified SENP EuB protease following this procedure:</p><p>&#8226; Prepare 10 &#181;M (0.32 &#181;g/&#181;L) of purified pTP396_His-Avi-SUMO Eu -anti-GFP Nb in 10 &#181;L of resuspension buffer, with and without 250 nM purified SENP EuB</p><p>&#8226; Incubate both reactions on ice for 20 min &#8226; Add 10 &#181;L of 2&#215; SDS-PAGE sample buffer to each sample and load half the volume (10 &#181;L, ~1.6 &#181;g of pTP396) in each lane &#8226; Analyze the test cleavage by SDS-PAGE and Coomassie staining. The expected outcome is shown in Fig. 4a &#8226; &#9650; CRITICAl STEP This is an optional quality control or troubleshooting step for the purified SENP EuB protease. Nonfunctional SENP EuB protease preparations will preclude successful elution of the affinity isolated POI in Part 3. &#9670; TROuBlESHOOTING Table 2 | Properties of all purified proteins Construct Protein M w (kDa) &#949; 280 (M -1 cm -1 ) pTP396 His 14 -Avi-27xGS-SUMO Eu -19xGS-anti GFP Nb 31.8 33,920 pTS117 His 14 -Avi-45xGS-anti GFP Nb 21.2 32,430 pTP298 His 14 -Avi-27xGS-SUMO Eu -2xGS-anti ALFA Nb 31.2 25,440 pTS118 His 14 -Avi-45xGS-anti ALFA Nb 20.6 23,950 pAV0286 His 14 -TEV-SENP EuB protease 32.4 45,380 pTP264 His 14 -bdNEDD8-BirA 48.9 50,420 &#949; 280 , extinction coefficient at 280 nm; M w , molecular weight. Protocol Part 2: generation of a stable human suspension cell line &#8226; TIMING 8 d Production of high-titer lentiviral supernatants &#8226; TIMING 5 d &#9650; CRITICAl Preparation of a stable human suspension cell line (Step 35) can be started in parallel to Step 1. 35. Thaw a single frozen aliquot of Lenti-X 293T cell, containing ~8-10 &#215; 10 6 cells, in a water bath at 37 &#176;C and add thawed cells to 10 mL of DMEM:FBS:Gln medium in a 15 mL tube. 36. Spin the culture for 3 min at 300g to pellet cells and remove DMSO. 37. Carefully aspirate the supernatant and resuspend the cell pellet in 1 mL of DMEM:FBS:Gln medium. 38. Add the cell suspension drop wise into a 15 cm dish containing 19 mL of DMEM:FBS:Gln medium. Distribute cells evenly using a careful 'figure eight' motion and incubate at 37 &#176;C, in a 5% CO 2 cell culture incubator for 16-28 h. &#9650; CAuTION Lentivirus and cell cultures are a potential biological hazard. Make sure to work in a certified biosafety cabinet and use proper sterile techniques. Adhere to the relevant institutional and governmental guidelines for recommended PPE and proper disposal of waste. &#9650; CRITICAl STEP Prevent Lenti-X 293T cells from reaching confluency. We typically split cells 1:10 every 2 d. Treat these cells very gently to preserve high transfection efficiency, which is essential to reach a high lentiviral titer. Freeze aliquots of very early passages and avoid prolonged culture (&lt;1 month). 39. Once the cells in the 15 cm dish have reached ~70% confluency, aspirate all culture medium, and wash gently with 20 mL of DPBS. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p>43. Incubate the six-well plate for ~24 h at 37 &#176;C in a humidified 5% CO 2 cell culture incubator. &#9650; CRITICAl STEP 70-80% confluency produces the best lentiviral titers 44. (Optional) Freeze the excess of resuspended Lenti-X 293T cells from Step 42, following these steps:</p><p>&#8226; Pellet the cell suspension for 3 min at 300g at RT &#8226; Aspirate the supernatant and resuspend the pellet in DMEM:FBS:Gln containing 10% (vol/vol) DMSO &#8226; Make 1 mL aliquots (each containing ~8-10 &#215; 10 6 cells) and store them at -80 &#176;C for 24 h in a cell freezing container &#8226; Transfer frozen cell aliquots into a cryo-tank for long-term storage 45. Once the cells have reached 70-80% confluency, transfect using the following procedure:</p><p>&#8226; For each well of the six-well plate, mix the reagents in the amounts suggested in the table below:</p><p>Reagent Amount Opti-MEM I reduced-serum medium 250 &#181;L Transfer plasmid 1.25 &#181;g psPAX2 0.94 &#181;g pMD2.G 0.32 &#181;g &#8226; Mix well by pipetting and add 7.5 &#181;L TransIT 293 transfection reagent &#8226; Mix again by pipetting and incubate the reaction for 15 min at RT &#8226; Carefully dispense the newly formed transfection complexes to each well of the six-well plate in drops and mix the plate by swirling. Incubate the plate for 24-36 h, as in Step 43 Box 2</p><p>Assessing the biotinylation efficiency of the purified Nbs</p><p>&#8226; TIMING 4 h</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>&#9650; CRITICAl</head><p>The biotinylation efficiency of the purified Nbs can be assessed by testing their binding to streptavidin beads. Use prechilled buffer and handle tubes in an aluminum tube rack within an ice bath. Keep the magnetic rack on ice as well.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Procedure</head><p>1. Carefully resuspend magnetic streptavidin beads until the slurry is homogeneous and no clumps are left on the bottom or side of the bottle. 2. In a 1.5 mL tube, add 25 &#181;L of slurry into 1 mL of STB buffer and mix well by pipetting. 3. Retrieve beads by placing the tube into a magnetic rack, wait 30-60 s to collect beads on the magnet, and then aspirate all buffer. 4. Dilute 12 &#181;g of biotinylated Nb with STB buffer in 60 &#181;L final volume. Take an input sample by mixing 10 &#181;L of the dilution with 2.5 &#181;L of 5&#215; SDS-PAGE sample buffer in a clean 1.5 mL tube.</p><p>&#9650; CRITICAl STEP To assess biotinylation efficiency, it is essential to avoid oversaturating the beads. We found that the capacity of Pierce Streptavidin Magnetic Beads is ~0.5 &#181;g of biotinylated Nb fusion protein per 1 &#181;L slurry of beads. 5. Remove the tubes from step 3 from the magnetic rack and resuspend the beads with the remaining 50 &#181;L of diluted Nb.</p><p>6. Incubate the samples for 30 min on ice with occasional gentle flicking of the tube to prevent beads from settling. 7. Retrieve the beads by placing the tubes into a magnetic rack.</p><p>Pipette out the unbound fraction and take a sample by mixing 10 &#181;L of the unbound fraction with 2.5 &#181;L of 5&#215; SDS-PAGE sample buffer in a clean 1.5 mL tube. 8. Wash the beads quickly by resuspending them in 1 mL of STB buffer. 9. Retrieve beads immediately by placing the tube into a magnetic rack and aspirate the buffer. 10. Repeat steps 8-9 above for a total of two wash steps. 11. For the last wash step, resuspend the beads in 100 &#181;L of STB buffer to concentrate them in a smaller volume. Retrieve beads and remove the buffer completely. 12. Resuspend the beads in 60 &#181;L of 2&#215; SDS-PAGE sample buffer containing 0.5 M urea and boil for 10 min at 97 &#176;C in a heat block.</p><p>Retrieve the beads and transfer the elution sample into a new 1.5 mL Eppendorf tube. Boil samples of input and unbound fraction (Steps 4 and 7) under identical conditions. 13. Analyze the test binding by SDS-PAGE and Coomassie staining.</p><p>Load 12.5 &#181;L of input and unbound samples, as well as 10 &#181;L of the elution per lane. The expected outcome is shown in Fig. <ref type="figure">4b</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>&#9670; TROuBlESHOOTING</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p>&#9650; CAuTION Enhanced biosafety level measures are required for all the following steps. &#9650; CRITICAl STEP Transfer plasmids contain repetitive sequences and should be prepared from recombination-deficient (recA -) E. coli strains such as Stellar. &#9650; CRITICAl STEP If multiple six wells need to be transfected, prepare a master mix without transfer plasmid. Aliquot the master mix and add transfer plasmid, followed by TransIT 293 transfection reagent. 46. After 24-36 h, verify the transfection efficiency of each well by visually assessing the percentage of fluorescent cells on a tissue-culture microscope. Nonfluorescent wells usually indicate problems with transfection and will yield low lentiviral titers. &#9670; TROuBlESHOOTING 47. Place the plate back into the 37 &#176;C, 5% CO 2 cell culture incubator, for an extra 24 h. 48. 48 h after the transfection, individually collect the cell culture medium from each well (~2.5 mL) in sterile 5 mL tubes and spin for 5 min at 500g to remove cell debris. &#9650; CRITICAl STEP Use rotor buckets with aerosol-tight caps and assemble and disassemble them in the biosafety cabinet. 49. Collect the lentivirus-enriched supernatant in a clean 5 mL tube and use immediately to transduce Expi293F suspension cells (Step 54). &#9632; PAuSE POINT Single-use aliquots of lentiviral supernatants can be snap-frozen in liquid nitrogen for storage at -80 &#176;C for multiple months with only slight loss of viral titer. &#9650; CRITICAl Repeated freeze-thaw cycles result in substantial loss of lentiviral titer. It is best to not re-use once thawed aliquots.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Transduce and grow Expi293F suspension cells</head><p>&#8226; TIMING 8 d</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>&#9650; CRITICAl</head><p>Step 50 can be started in parallel to Steps 1 and 35 to allow the Expi293F cells to recover for a few days before transduction. 50. Thaw a 1 mL aliquot containing ~20 &#215; 10 6 Expi293F cells in a water bath at 37 &#176;C and add to 10 mL of Expi medium contained in a 15 mL tube. 51. Spin the cell suspension for 3 min at 300g to remove the DMSO. 52. Resuspend the cell pellet in 1 mL of Expi medium and transfer to 49 mL of the same medium in a 125 mL Erlenmeyer flask with a vented cap. 53. Grow Expi293F cells in a 37 &#176;C orbital shaker with 8% CO 2 , &gt;80% relative humidity and shaking at ~125 rpm for 72 h. &#9650; CRITICAl STEP While in culture, maintain Expi293F stock between 0.5 and 2 &#215; 10 6 cells/mL by diluting them 1:4 with fresh medium every 2 d. Freeze excess cells in Expi medium supplemented with 10% (vol/vol) DMSO to replenish cell aliquots. &#9650; CAuTION Enhanced biosafety level measures are required for all the following steps. 54. In a clean 125 mL Erlenmeyer flask with a vented cap, mix 20 mL of Expi293F cells at 1 &#215; 10 6 cells/mL density with 2.5 mL freshly collected lentiviral supernatant (Step 49). &#9650; CRITICAl STEP Transduction efficiency depends strongly on the lentiviral titer. This can be optimized by mixing a constant amount of suspension cells with increasing volume of lentiviral supernatant. If needed, this step can easily be scaled up or down. 55. Transfer the flask to a shaking incubator and grow the cells overnight using the same conditions as described in Step 53. 56. The next day, transfer the culture into a 50 mL tube, place into rotor buckets with aerosol-tight caps in the biosafety cabinet and spin at 300g for 3 min to pellet transduced cells for a medium exchange. 57. Take off supernatant by pipetting and mix it with 10% bleach to inactivate the lentivirus. 58. Resuspend the cell pellet (Step 56) in 50 mL of Expi medium and transfer to a new 125 mL Erlenmeyer flask with a vented cap. 59. Grow cells for 72 h as described in step 53. 60. Evaluate transduction efficiency by analyzing the ratio of fluorescent cells 48 h after transduction. This can be done visually, using a tissue culture microscope, more quantitatively via flow cytometry (Box 3) or by western blotting. If using Protocol inducible cells, take off 2 mL of culture to a six-well plate and induce for 24 h with 1 &#181;g/mL doxycycline (DOX) before analysis of transduction efficiency, as above. &#9670; TROuBlESHOOTING 61. For small-scale expression trials, grow 50 mL of culture volume to ~8 &#215; 10 6 cells/mL.</p><p>If the expressed protein is not toxic, there should not be a notable drop in cell viability. &#9650; CRITICAl STEP If using inducible cells, ensure to add 1 &#181;g/mL DOX to the culture medium. Induction time can be varied, but 24-48 h before collection is a good starting point. Before induction, take off an aliquot of noninduced cells as control, at a density of 0.5 &#215; 10 6 cells/mL in 50 mL and transfer them into a new flask to keep them in culture. 62. To collect cells, remove flasks from shaking incubator. If using noninducible cells, count cells and make up a separate stock at ~0.5 &#215; 10 6 cells/mL in 50 mL in a new flask to keep them in culture in case sorting is necessary or the culture needs to be expanded for large-scale preparations. 63. Transfer the remaining cells into a 50 mL tube and pellet cells as described in Step 56. 64. Wash the pellet by resuspending it in 50 mL of DPBS and repeat the centrifugation as in</p><p>Step 56. 65. Pour off the supernatant, weigh the dry cell pellet and proceed directly to cell lysis.</p><p>&#9632; PAuSE POINT Alternatively, cell pellets can be frozen in liquid nitrogen and stored at -80 &#176;C for multiple months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Box 3</head><p>Sorting of transduced Expi293F cells</p><p>&#8226; TIMING 7-9 d Procedure 1. Collect 45 &#215; 10 6 transduced and nontransduced Expi293F cells as described in Steps 63-65. 2. Resuspend the washed cell pellets in 3 mL of DPBS supplemented with 20% (vol/vol) FBS to a concentration of ~15 &#215; 10 6 cells/mL. 3. Filter the resuspended cells through strainer caps into 5 mL round-bottom flow cytometry tubes and place the tubes on ice. 4. Analyze the nontransduced Expi293F cells and other relevant controls on a SONY SH800S cell sorter or equivalent, and adjust gates to select alive cells (using a FSC-Area versus SSC-A gate) and single cells (using a FSC-H versus FSC-A gate), as well as to determine background fluorescence level. Set gate for transduced fluorescent cells accordingly (e.g., using a GFP-A versus FSC-A gate to sort GFP-positive cells). 5. Collect at least 2-4 &#215; 10 6 cells in a 15 mL collection tube prefilled with 3 mL Expi medium containing 0.5&#215; pen-strep.</p><p>&#9650; CRITICAl STEP Since most cell sorters are not operated under perfectly sterile conditions, it is essential to add pen-strep to prevent contamination. However, only 0.5&#215; pen-strep is used since Expi293F cells are more sensitive to antibiotics than regular HEK 293T cells. 6. Pellet collected cells to remove sheath fluid by centrifuging at 300g for 3 min at RT. 7. Resuspend the cell pellet in 10 mL Expi medium containing 0.5&#215; pen-strep. 8. Transfer all of the cell suspension to a new empty 125 mL Erlenmeyer flask with a vented cap and grow overnight in a 37 &#176;C orbital shaker with 8% CO 2 , &gt;80% relative humidity and shaking at ~125 rpm. 9. 24 h after sorting, pellet cells as in Step 6 and aspirate the supernatant. 10. Resuspend the cell pellet in 10 mL of Expi medium without pen-strep and transfer the culture back to the same flask.</p><p>&#9650; CRITICAl STEP Prolonged exposure to pen-strep reduces cell viability.</p><p>11. Let cells recover by growing them for 5-7 d as described in Step 8. Assess cell density every day, replenish medium and dilute cells to grow up a new stock of sorted cells. Freeze aliquots of early passages.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell lysis</head><p>&#8226; TIMING 2 h 66. Lyse cells by performing mechanical lysis without detergent (Option A) or lysis in detergent (Option B). Refer to the 'Experimental design' section for guidance on choosing a lysis method.</p><p>(A) Mechanical lysis without detergent (i) Resuspend the cell pellet (Step 65) in pre-chilled lysis buffer using ~7 mL per 1 g of cell pellet as a starting point. &#9650; CRITICAl STEP Lysis buffer composition and volume is protein specific and should be optimized in small-scale experiments. &#9650; CRITICAl STEP If frozen cell pellets are used, add lysis buffer to the frozen pellet and then thaw quickly in a lukewarm water bath at RT. Remove to ice immediately once thawing nears completion. (ii) Lyse the cells in dounce homogenizer with ~30-50 vertical strokes of a tight fit pestle. Alternatively, use a motor-driven Potter-Elvehjem homogenizer. (iii) Monitor the progression of cell lysis on a cell counter or tissue-culture microscope using trypan blue exclusion and continue lysing the cells until no more intact cells remain. (iv) Remove cell debris by centrifuging the lysate for 30 min at 35,000g and 4 &#176;C. (v) Collect the supernatant, take a sample for SDS-PAGE and proceed to affinity purification (Step 74). (B) lysis in detergent &#9650; CRITICAl Optimal detergent type and salt concentration, as well as the ratio of solubilization buffer to cell pellet weight is membrane protein as well as application specific, and should be optimized in small-scale experiments. We routinely solubilize whole cell pellets, but in certain cases it is advantageous to prepare a membrane fraction before solubilization. The steps below offer a good starting point. (i) Solubilize the cell pellet by adding 7 mL of prechilled solubilization buffer containing 1% (wt/vol) of a detergent of choice per each gram of cell pellet and resuspend by pipetting. &#9650; CRITICAl STEP If using frozen cell pellets, add solubilization buffer directly to frozen cells and then thaw quickly in a lukewarm water bath at RT. Remove to ice immediately once thawing nears completion. (ii) Incubate the suspension by mixing head-over-tail for 30 min at 4 &#176;C. (iii) Discard cellular debris by centrifuging the lysate for 30 min at 35,000g and 4 &#176;C. (iv) Collect the supernatant, take a sample for SDS-PAGE and proceed to affinity purification (Step 74).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Part 3: affinity purification</head><p>&#8226; TIMING 3 h &#9650; CRITICAl The amount of beads and Nb needed depend on the expression level of the POI and should be optimized in small-scale experiments. The steps below offer a good starting point. Use prechilled buffer and handle tubes in an aluminum tube rack within an ice bath. Keep the magnetic rack on ice as well. &#9650; CRITICAl Solubilization and wash buffers contain 1 mM DTT, which might reduce disulfide bonds in proteins that contain them. If your POI contains disulfide bonds, leave out DTT. 67. For every gram of cell pellet, equilibrate 60 &#181;L of magnetic streptavidin beads slurry. Carefully resuspend the beads until the slurry is homogeneous and no clumps are left on the bottom or side of the bottle. Aliquot 60 &#181;L of slurry into a 1.5 mL tube. 68. Retrieve beads by placing the tubes into a magnetic rack, wait for 30 s to 1 min to collect all beads and aspirate all liquid. 69. Wash the beads by resuspending them in 1 mL of wash buffer, retrieve beads as in Step 68 and aspirate the wash buffer. &#9650; CRITICAl STEP For membrane proteins, the wash buffer should be supplemented with a detergent at a concentration above its critical micelle concentration to keep the protein solubilized. We recommend using a concentration that corresponds to 2.5&#215; critical micelle concentration.</p><p>Protocol 70. For every 60 &#181;L of magnetic streptavidin beads slurry, immobilize 20 &#181;g of biotinylated GFP or ALFA Nb. Resuspend the beads in 500 &#181;L of wash buffer containing prediluted biotinylated Nb and incubate the slurry for 15 min, mixing head-over-tail at 4 &#176;C. 71. Retrieve the beads using a magnet as in Step 68 and aspirate the wash buffer. Remove the tubes from the magnetic rack and resuspend the beads in 500 &#181;L of wash buffer containing 100 &#181;M biotin or dPEG 24 -biotin acid. 72. Incubate the suspension for 5 min, leaving the tube resting on ice to block unoccupied biotin binding sites on streptavidin. &#9650; CRITICAl STEP Blocking with biotin strongly reduces background binding of endogenous biotinylated proteins. Blocking with dPEG 24 -biotin acid adds additional negative charge and further reduces nonspecific background binding to the beads. 73. Retrieve the beads using a magnetic rack (Step 68) and aspirate the blocking buffer. 74. Resuspend the beads with 1 mL of cleared cell lysate and add to the remainder of cell lysate in a clean 5, 15 or 50 mL tube, depending on scale. Mix the tube rapidly by inversion. 75. Incubate the mixture for 1 h at 4 &#176;C, rotating. 76. Retrieve the beads using a magnetic rack (Step 68). Depending on the final scale, a magnetic rack that can hold 15 mL or even 50 mL tubes should be used at this step. Take a sample of the cleared cell lysate (unbound fraction) for SDS-PAGE. 77. Aspirate the cell lysate, resuspend the beads in 1 mL of wash buffer and transfer them into a clean 1.5 mL tube. 78. Retrieve beads immediately using a magnetic rack (Step 68). 79. Wash beads three times with 1 mL wash buffer within the same tube, performing Steps 77-78. 80. For the fourth wash, resuspend beads with 100 &#181;L wash buffer (-ATP) and transfer to a new tube. Use slightly more volume if more beads were used. 81. Resuspend the beads in wash buffer containing 250 nM purified SENP EuB for the isolation of target protein in its tagged (TagON) or untagged (TagOFF) form. Use a volume corresponding to the original volume of bead slurry used. To keep the eluate more concentrated, up to one-third of the original volume can be used. &#9650; CRITICAl STEP If a soluble protein is stable in the presence of detergents (such as 0.05% (vol/vol) Tween-20 or Triton-X-100), these can be included during elution to improve recovery by preventing nonspecific binding of the cleaved protein to the beads. 82. Incubate the samples for 20 min on ice for protease elution to complete. 83. Retrieve beads using a magnetic rack (Step 68) and collect the supernatant by pipetting and transfer into a clean 1.5 mL tube. Keep tube with beads for postelution as described in Steps 86-87. 84. Spin eluate for 5 min at 15,000g at 4 &#176;C to pellet magnetic beads that sometimes get carried over. 85. Collect the supernatant again by pipetting and transfer into a clean 1.5 mL tube. This is your final native elution sample containing your purified POI and can be used directly for structural and functional assays. Take a sample for SDS-PAGE. Alternatively, the purified protein can be flash-frozen in multiple aliquots in liquid nitrogen for storage at -80 &#176;C. &#9650; CRITICAl STEP Freeze-thawing purified proteins might substantially decrease sample quality. Always perform a test freeze-thaw cycle with a small aliquot and verify protein quality using your assay of choice.</p><p>86. To analyze what remained on the beads, resuspend the beads from Step 83 in 2&#215; SDS-PAGE sample buffer containing 0.5 M urea and boil for 10 min at 97 &#176;C. 87. Retrieve beads using a magnetic rack and collect postelution sample. 88. Analyze samples of the eluate and postelution by SDS-PAGE. It is recommended loading 1, 2 and 4 &#181;L per lane and stain the gel with either Sypro Ruby or Coomassie. Samples of the cell lysate before (Steps 66a(v) and 66b(iv)) and after (Step 76) affinity purification can be analyzed by western blotting with a POI-or tag-specific antibody to assess the degree of depletion of the tagged POI from the lysate. &#9670; TROuBlESHOOTING 89. (Optional) Perform a SEC run of the native elution sample from Step 85 to remove excess tagged subunit and Nb, and to improve sample homogeneity (Box 4). Protocol Timing Part 1: Steps 1-34, generation of biotinylated nanobodies, SENP EuB , and biotin ligase BirA: 4-5 d Steps 1-6, transformation E. coli cells via heat shock: 1 d Steps 7-9, starting a preculture: 1 d Steps 10-15, starting and inducing the main culture: 1 d Steps 16-18, collect the main culture and freeze resuspended cell pellet: 1 h Steps 19-22, thaw frozen cells for cell lysis by sonication: 1 h Steps 23-28, binding to Ni 2+ -chelate affinity resin and elution: 3 h Steps 29-32, concentration assessment and storage: 1 h Step Problem Possible reason Solution 46 Transfected Lenti-X 293T cells nonfluorescent Poor DNA quality Check plasmid DNA integrity and prepare new stock. Perform additional wash steps during DNA Mini or Maxi prep as outlined in your kit's manual 60 Low transduction efficiency Bad cell health: Lenti-X 293T cells passaged for prolonged time and/or overgrown before seeding Thaw a new Lenti-X 293T cell aliquot and avoid overgrowing and passaging them &gt;1 month Transfected Lenti-X 293T cells at too high or too low confluency Make sure to transfect at ~70-80% confluency Forgot or added wrong amounts or bad quality of packaging and envelope plasmids Make sure to add correct amounts of packaging and envelope plasmids and consider preparing new stocks DNA insert size comes close to or exceeds packaging limit (~8 kbp between 5&#8242; and 3&#8242; LTRs) Sort transduced cells and grow up a fully transduced population POI is toxic to cells Try using inducible Expi293F TetR+ cell line, expressing an inactive mutant, or transient expression via chemical transfection 88 Low protein yield from Expi293F cells Poor lentiviral titer or transduction efficiency Repeat lentiviral preparation or sort transduced cells and grow up a fully transduced population Inefficient protease elution Analyze postelution sample by SDS-PAGE and check for uncleaved bait (TagON) or bait-prey complex (TagOFF). Check protease activity in solution (Step 34) and repeat protease preparation if inactive. In some cases, the SUMO tag may be less accessible, requiring increased protease concentration and incubation time to achieve efficient elution Eluted protein non-specifically sticks to beads (sometimes for soluble proteins in buffer without detergent) Include low concentration of detergent (e.g., 0.05% (vol/vol) Tween-20 or Triton-X-100) in elution buffer to reduce sticking. Block streptavidin beads with biotin-PEG-COOH instead of biotin to increase charge repulsion between beads and protein. The cleaved protein may be released in additional wash steps Protein aggregated due to suboptimal lysis buffer composition Optimize lysis buffer composition e.g., salt, or detergent concentration in small-scale pretests Low recovery of the prey's endogenous protein complex subunits Tagged protein is stable on its own after overexpression Consider tagging a different, less stable subunit of the complex. Alternatively: (1) use Freestyle 293-F cells instead; (2) use inducible Expi293F cell line and vary DOX induction time; (3) exchange CMV to weaker PGK or UbC promoter or remove WPRE element; (4) purify membrane proteins from the membrane fraction rather than whole cells Insufficient depletion of the tagged POI from input cell lysate detected by western blotting Not enough Nb or beads were used Immobilize more Nb on more beads per gram of cell pellet to increase depletion of tagged POI and therefore final yield Box 2, step 13 GFP Nanobodies produced in E. coli AVB101 do not bind to streptavidin beads Forgot to supplement AVB101 main culture with biotin or forgot to use cam to maintain BirA plasmid Make sure to propagate AVB101 with 10 &#181;g/mL cam and add 50 &#181;M biotin to main culture In vitro biotinylated ALFA nanobodies do not bind to streptavidin beads Poor quality BirA preparation or wrong biotinylation buffer composition Check BirA by SDS-PAGE and check 5&#215; biotinylation buffer composition. Repeat BirA preparation</p><p>Table 3 (continued) | Troubleshooting table Protocol Step 33, (Optional) assessment of biotinylation efficiency: 4 h Step 34, (Optional) assessment of SENP EuB protease activity: 3 h Part 2: Steps 35-66, generation of a stable human suspension cell line: 8 d (unsorted), 15 d (sorted) Steps 35-49, production of high-titer lentiviral supernatants: 4 d Steps 35-38, culture Lenti-X 293T cells: 1 d Steps 39-44, seed Lenti-X 293T cells into six-well plates: 1 d Step 45-47, transfection and lenti production: 2 d Steps 48-49, collect lentiviral supernatant: 0.5 h Steps 50-61, transduce and grow Expi293F suspension cells: 8 d Steps 50-53, culture Expi293F cells: 3 d Steps 54-55, transduce with collected lentiviral supernatant: 1 d Steps 56-59, exchange medium: 0.5 h Step 60, evaluation of transduction efficiency: 0.5 h Step 61, growth phase: 4 d Steps 62-65, cell collection: 1 h Step 66, cell lysis: 2 h Part 3: Steps 67-89, affinity purification: 3 h</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Anticipated results</head><p>This protocol has been successfully used to isolate numerous soluble and membrane-bound proteins for structural, functional and mass spectrometry analysis (Fig. <ref type="figure">5</ref>). In particular, to demonstrate the utility of both (TagON and TagOFF) purification strategies, we used the nine-subunit EMC as a model substrate. GFP-or ALFA-tagged EMC2 or EMC5 are incorporated into the EMC in place of their respective endogenous subunits, allowing the intact complex to be isolated in high purity (Fig. <ref type="figure">5a</ref>,<ref type="figure">b</ref>). Using the TagOFF strategy, capture of GFP-SUMO Eu -EMC2 with a noncleavable anti-GFP Nb allowed isolation of completely untagged EMC under native conditions following SENP EuB cleavage, while the affinity tag and Nb were retained on the beads. As a proof-of-concept, we successfully isolated other challenging soluble and membrane protein complexes by tagging a single subunit (Fig. <ref type="figure">5c</ref>). For example, GFP-SRP72 efficiently incorporated into the ribonucleoprotein signal recognition particle (SRP), which could be isolated under native conditions. Purified SRP was fully functional and bound to stalled ribosome nascent chains exposing a transmembrane domain in a hydrophobicity sensitive manner as observed before for endogenous SRP <ref type="bibr">50</ref> (Fig. <ref type="figure">5d</ref>). Similarly, we used this strategy to isolate the entire 26S proteasome from cells expressing GFP-tagged RPN11, the ER-resident membrane protein complex NOMO-NCLN-TMEM147 via TMEM147-GFP, and the plasma membrane localized anion exchanger SLC4A2/AE2. Our strategy also guarantees improved yields for challenging multisubunit membrane protein complexes. For example, we could isolate 0.45 mg of EMC or ~0.8 mg of MTCH2 per 1 L of suspension cell culture. Much greater yields can be achieved for soluble protein complexes and, in particular, for soluble monomeric proteins. Another critical consideration for the success of the protocol is to take great care to achieve high-titer lentiviral production as outlined above. Only with good lentiviral preparations can high transduction efficiencies of suspension cells be reached. In many cases, transduction efficiencies are readily between 80% and 90%, as can be seen for the transduction of Expi293F cells with an EMC3-GFP-encoding lentivirus (Fig. <ref type="figure">6a</ref>,<ref type="figure">b</ref>). The high percentage of GFP-positive cells allowed direct purification of EMC3-GFP-containing EMC complexes without prior sorting of the cell line (Fig. <ref type="figure">6c</ref>). In certain cases, (e.g., for much larger proteins) lower transduction efficiencies necessitate either larger-scale cultures to achieve a comparable yield or an additional sorting step (Box 3) to obtain a fully transduced Extended Data Fig. 1 | Overview of anti-GFP nanobody compatible fluorescent protein variants. (a) Crystal structure of GFP bound to anti-GFP nanobody (Nb) (PDB ID: 3K1K) 43 with GFP shown in green with cartoon rendering, anti-GFP Nb shown in blue with surface rendering, and specific residues on GFP that make contact with the anti-GFP Nb shown in stick rendering. (b) Front-view of the anti-GFP nanobody binding surface of GFP with participating residues shown in stick rendering. Residues mutated in other fluorescent protein variants colored in salmon. (c) Multiple sequence alignment of various fluorescent protein variants. Columns corresponding to residues contacted by the anti-GFP Nb are highlighted in yellow, and any mutations to these positions are highlighted in red. Mutation of I146N was previously shown to restore anti-GFP Nb binding in CFP variants 53 .</p></div></body>
		</text>
</TEI>
